The report provides a detailed analysis essential for establishing an Alendronate Sodium production plant. It encompasses all critical aspects necessary for Alendronate Sodium production, including the cost of Alendronate Sodium production, Alendronate Sodium plant cost, Alendronate Sodium production costs, and the overall Alendronate Sodium Production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Alendronate Sodium production plant. These encompass Production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Alendronate Sodium is an anti-resorptive medicine that has been approved by the FDA for the treatment of Paget’s disease of the bone, treatment of osteoporosis in men, postmenopausal osteoporosis, and osteoporosis induced by steroids. It belongs to the bisphosphonate medicine class, which has the characteristic of strengthening the volume of bones and preventing resorption.
It is also prescribed for other diseases, which include Crohn-induced osteoporosis, osteopenia with cystic fibrosis, fibrous dysplasia, growth hormone deficiency, and hypercalcemia of malignancy. Moreover, it is also utilized together with testosterone replacement for the longer term to help increase the femur neck BMD (bone mineral density) in men with osteoporosis and hypogonadism. Further, in pediatric patients, off-label uses of Alendronate Sodium include disorders like secondary amenorrhea, hypervitaminosis D, and bone necrosis.
The market for Alendronate Sodium is driven by its usage as an FDA-approved medication used for the treatment of different types of osteoporosis, which significantly promotes its demand in the pharmaceutical and medical industries. The widespread occurrence of osteoporosis is significantly increasing the demand for Alendronate Sodium. It witnesses a significant demand from the aging population as they are more likely to be affected by conditions such as osteoporosis and related bone disorders. Additionally, its utilization beyond the treatment of osteoporosis for conditions such as Crohn-induced osteoporosis, osteopenia with cystic fibrosis, fibrous dysplasia, growth hormone deficiency, and hypercalcemia of malignancy, secondary amenorrhea, hypervitaminosis D, and bone necrosis, amplifies its market presence.
Furthermore, its ability to be used in combination with testosterone replacement therapy to improve bone mineral density in men who have osteoporosis and long-standing hypogonadism further contributes to its demand. Overall, industrial Alendronate Sodium procurement is influenced by its application in the pharmaceutical and medication industries, rising cases of osteoporosis and other bone-related disorders, the aging population, off-label uses, combination therapy, and regulatory approvals.
Raw Material for Alendronate Sodium Production
According to the Alendronate Sodium production plant project report, the key raw material used in the production of Alendronate Sodium includes γ-aminobutyric acid.
Production Process of Alendronate Sodium
The extensive Alendronate Sodium production cost report consists of the following major industrial production process:
- Production from γ-aminobutyric acid: The production process of Alendronate Sodium starts with the treatment of γ-aminobutyric acid with phosphorus trichloride and phosphoric acid in the presence of chlorobenzene followed by quenching with water to form Alendronic acid. Finally, Alendronic acid is converted into sodium salt using sodium hydroxide in an appropriate medium to produce Alendronate Sodium.
Alendronate Sodium, commercially known as Fosamax, is a white crystalline solid having the molecular formula C4H18NNaO10P2 and a molecular weight of 325.12 g/mol. It is soluble in water with an estimated water solubility of 23.7 mg/mL but insoluble in chloroform. It has a melting point in the range of 257-270°C and a boiling point of around 617°C. It is a second-generation bisphosphonate medication used to treat osteoporosis and Paget's disease of bone.
